Under the therapeutic pressure of NHT, prostate cancer cells may upregulate GR and PR, activating pathways typically stimulated by AR, thereby sustaining tumor cell proliferation and survival [24,25]. This evidence concerns the gene NR3C1 and prostate carcinoma.